<DOC>
	<DOCNO>NCT00361803</DOCNO>
	<brief_summary>A multi-center , open label , single dose Phase I pharmacokinetic ( PK ) characterization weekly IV ( intravenous ) topotecan give 4mg/m2 . 15 patient evaluate .</brief_summary>
	<brief_title>Topotecan Pharmacokinetic Characterization Study</brief_title>
	<detailed_description />
	<mesh_term>Topotecan</mesh_term>
	<criteria>Inclusion criterion : Written inform consent Performance status 0 , 1 , 2 Eastern Cooperative Oncology Group ( ECOG ) Scale Predicted life expectancy least 3 month Subjects histologically cytologically confirm advanced solid tumor fail conventional therapy tumor type tumor type standard effective therapy exist ; OR Patients singleagent topotecan therapy suitable At least 4 week since last chemotherapy , radiotherapy , biologic therapy surgery Must free posttreatment side effect ( exception alopecia ) No concurrent chemotherapy , biologic therapy radiotherapy allow Hemoglobin = 9.0 g/dL WBC = 3,500/mm3 [ = 3.5 x 109/L ] Neutrophils = 1,500/mm3 [ = 1.5 x 109/L ] Platelets = 100,000/mm3 [ = 100.0 x 109/L ] Calculated creatinine clearance=60 mL/min use CockcroftGault formula Serum bilirubin &lt; 2.0 mg/dL ( 34 Âµmol/L ) AST , SGPT/ALT alkaline phosphatase &lt; 2 time upper limit normal liver metastasis visualize abdominal compute tomography ( CT ) magnetic resonance imaging ( MRI scan ) If liver metastases present , subject &lt; 5 time upper limit normal eligible participate Exclusion criterion : Women pregnant lactate Women subject childbearing potential refuse abstain sexual intercourse practice adequate contraception . Childbearing potential defined woman surgically sterilize ( i.e . hysterectomy , bilateral oophorectomy [ ovariectomy ] , bilateral tubal ligation ) postmenopausal ( i.e. , document absence menses one year prior entry study ) . Men unwilling abstain sex use effective contraception study 3 month follow completion topotecan treatment Subjects uncontrolled emesis , regardless etiology Active infection Concurrent severe medical problem unrelated malignancy , would significantly limit full compliance study expose patient extreme risk Treatment another investigational drug within 30 day five halflives prior entry study ( whichever longer ) History allergic reaction compound chemically related topotecan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>chemotherapy</keyword>
	<keyword>recurrent</keyword>
	<keyword>refractory</keyword>
	<keyword>research</keyword>
	<keyword>cancer</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>